Citations

Showing 10 of 108119 citations.

Targeting Peroxisome Proliferator-Activated Receptor-Gamma Decreases Host Mortality After Influenza Infection in Obese Mice
Huang, Su, Jiang, Li , Cheon, In Su , Sun, Jie

Mayo Clinic

Viral Immunology | April 22, 2019 | Volume: 32 | Issue: 4 | Pages: 161-169

10.1089/vim.2019.0016 | PMID 31009317 Get It

Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).
Yasenchak, Christopher A. , Ansell, Stephen M. , Knapp, Mark, Fayad, Luis , Patel‐Donnelly, Dipti, Seetharam, ­Mahesh , Yimer, Habte, Manley, Thomas, Burke, John M. , Holkova, Beata , Bartlett, Nancy L. , Farber, Charles Michael , Advani, Ranjana H. , Kolibaba, Kathryn S. , Budde, Lihua E. , Halwani, Ahmad

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8506-8506

10.1200/jco.2015.33.15_suppl.8506 Get It

Evaluation of complete response rate at 30 months (CR30) as a surrogate for progression-free survival (PFS) in first-line follicular lymphoma (FL) studies: Results from the prospectively specified Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH
Bedout, Sabine De, Flowers, Christopher R. , Fowler, Nathan , Hagenbeek, Anton, Herold, Michael , Huang, Jane , Nielsen, Tina, Takeshita, Kenichi , Valente, Nancy, group, the FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis), Sargent, Daniel J. , Shi, Qian , Fu, Tommy , Hoster, Eva , Kimby, Eva , Ladetto, Marco , Morschhauser, Franck , Vitolo, Umberto , Zucca, Emanuele , Salles, Gilles , group, the FLASH (Follicular Lymphoma Analysis of Surrogacy Hypothesis)

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8504-8504

10.1200/jco.2015.33.15_suppl.8504 Get It

Combination of everolimus with R-CHOP (ever R-CHOP) as an initial therapy for diffuse large B-cell lymphoma (DLBCL): A phase I and feasibility study (NCCTG N1085 [Alliance]).
Johnston, Patrick B. , LaPlant, Betsy, Nowakowski, Grzegorz S. , Micallef, Ivana N. , Ansell, Stephen M. , Habermann, Thomas M. , Colgan, Joseph P. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8518-8518

10.1200/jco.2015.33.15_suppl.8518 Get It

Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.
Landau, Heather , Comenzo, Ray, Weiss, Brendan M. , Zonder, Jeffrey A. , Walling, Jackie , Kinney, Gene G. , Koller, Marty, Liedtke, Michaela , Gertz, Morie A. , Seldin, David C.

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8514-8514

10.1200/jco.2015.33.15_suppl.8514 Get It

A novel muscle cramp scale (MCS) in amyotrophic lateral sclerosis (ALS)
Mitsumoto, Hiroshi , Chiuzan, Codruța , Gilmore, Madison , Zhang, Yuan , Ibagon, Camila , McHale, Brittany , Hupf, Jonathan , Oskarsson, Björn , Oskarsson, Björn

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | April 22, 2019 | Volume: 20 | Issue: 5-6 | Pages: 328-335

10.1080/21678421.2019.1603310 | PMID 31007059 Get It

Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Forero‐Torres, Andres , Sher, Taimur , Scherle, Peggy , Schaub, Richard, Zhou, Li , Pulini, Jennifer, Leopold, Lance, Spear, Matthew A. , Phillips, Tycel , Diefenbach, Catherine , Talpaz, Moshe , Barr, Paul M.

Mayo Clinic

Journal of Clinical Oncology | April 22, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8520-8520

10.1200/jco.2015.33.15_suppl.8520 Get It

Subtyping of non-small cell lung cancer by cytology specimens: A proposal for resource-poor hospitals
Bulut, Tangül, Khoór, András , Celik, Betul, Çelik, Betül

Mayo Clinic

CytoJournal | April 22, 2019 | Volume: 16 | Issue: No issue available | Pages: 8

10.4103/cytojournal.cytojournal_19_18 | PMID 31080486 Get It

Aim:Cancer diagnosis and treatment depend on pathology reports but naming a cancer is sometimes impossible without specialized techniques. We aimed to evaluate the sensitivity of cytological sub-classification of non-small cell lung carcinoma, not otherwise specified group (NSCLC-NOS) into Adenocarcinoma (AC) and Squamous cell carcinoma (SqCC) without using immunohistochemistry.Methods:Endobronchial ultrasound guided fine-needle aspiration biopsies and cytology slides diagnosed as NSCLC-NOS between 2004- 2008 were reviewed retrospectively. The final diagnosis was reached by immunohistochemistry (TTF-1, p63) when necessary.Results:One hundred-twenty nine cases were retrieved. The final diagnoses were as follows: SqCC: 30.3%; AC: 65.7%; combined tumor (3 adenosquamous and 1 small cell + SqCC): 4%. Cytological diagnoses rendered were as follow: Definitely SqCC: 10.1%; favor SqCC: 14.1%; definitely AC: 38.4%; favor AC: 35.4%; NSCLC-NOS: 2%. The sensitivity and specificity of cytology were 86.3 and 87.5% for AC diagnosis respectively.Conclusion:Positive and negative predictive value of cytology was 95.3% and it was even 100% for well to moderately differentiated tumors. There was a tendency to sub-classify poorly differentiated SqCC as AC. Papanicolaou stain increased the diagnostic accuracy of SqCC. The combined tumor rate was 4% and after recognizing a tumor component, the second component was missed if the slide examination was terminated prematurely.
Mexiletine Shortens the QT Interval in Patients With Potassium Channel–Mediated Type 2 Long QT Syndrome
Bos, J. Martijn , Crotti, Lia , Rohatgi, Ram K., Castelletti, Silvia , Ackerman, Michael J. , Crotti, Lia , Bos, Johan M , Dagradi, Federica , Schwartz, Peter J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 22, 2019 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/circep.118.007280 | PMID 31006312 Get It

Background: Long QT syndrome is a potentially lethal yet highly treatable cardiac channelopathy. Although β-blocker therapy is standard for most patients, concomitant therapy with sodium channel blockers, like mexiletine, is often utilized for patients with sodium channel–mediated type 3 long QT syndrome (LQT3). The potential role of sodium channel blockers in patients with potassium channel–mediated long QT syndrome (ie, LQT1 and LQT2) has not been investigated in detail. Methods: We performed a retrospective chart review on 12 patients (5 females; median age at diagnosis 14.1 years (interquartile range [IQR], 7.7–23; range, 0–59, median heart rate–corrected QT interval [QTc] at diagnosis 557 ms (IQR, 529–605) with genetically established LQT2 (10) or a combination of LQT1/LQT2 (1) or LQT2/LQT3 (1), who received mexiletine. Data were collected on symptomatic status, treatments, and breakthrough cardiac events after diagnosis and initiation of treatment. Additionally, 12-lead ECGs were collected at diagnosis, before initiation of mexiletine and following mexiletine to evaluate the drug’s effect on QTc. Results: Before diagnosis, 6 patients were symptomatic and, before initiation of mexiletine, 4 patients experienced ≥1 breakthrough cardiac event on β-blocker. Median age at first mexiletine dose was 24.3 years (IQR, 14–32.4). After mexiletine, the median QTc decreased by 65±45 ms from 547 ms (IQR, 488–558) premexiletine to 470 ms (IQR, 409–529) postmexiletine ( P =0.0005) for all patients. In 8 patients (67%), the QTc decreased by ≥ 40 ms with a mean decrease in QTc of 91 ms ( P < 0.008). For the 11 patients maintained on mexiletine therapy, there have been no breakthrough cardiac events during follow-up. Conclusions: Although commonly prescribed in patients with LQT3, mexiletine also shortens the QTc significantly in two-thirds of a small subset of patients with potassium channel–mediated LQT2. In patients with LQT2, pharmacological targeting of the physiological late sodium current may provide added therapeutic efficacy to β-blocker therapy.
Detection of extranodal and spleen involvement by FDG‐PET imaging predicts adverse survival in untreated follicular lymphoma
St‐Pierre, Frédérique , LaPlant, Betsy, Ristow, Kay M., Macon, William R. , Ansell, Stephen M. , Thompson, Carrie A. , Micallef, Ivana N. , Nowakowski, Grzegorz S. , LaPlant, Betsy R, Ristow, Kay, Ansell, Stephen M , Micallef, Ivana N M, Witzig, T.E. , Broski, Stephen M. , Maurer, Matthew J. , Habermann, Thomas M. , Witzig, Thomas E.

Mayo Clinic

American Journal of Hematology | April 22, 2019 | Volume: 94 | Issue: 7 | Pages: 786-793

10.1002/ajh.25493 | PMID 31006875 Get It

AbstractPredicting early clinical failure in patients with untreated follicular lymphoma (FL) is important but difficult. This study aimed to determine the incidence and patterns of extranodal (EN) and spleen disease using PET/CT, and assess their utility in predicting early clinical failure. PET/CT images from 613 cases of untreated FL (2003‐2016) were reviewed. The location and number of EN sites, patterns of bone involvement, and splenic involvement were recorded. Outcomes were assessed using event‐free survival (EFS), overall survival (OS), and early clinical failure at 24 months (EFS24). So, 49% (301/613) of patients had PET/CT‐detected EN involvement, and 28% (171/613) had spleen involvement. The presence of ≥2 EN sites, spleen, bone or soft tissue involvement all predicted failure to achieve EFS24. Presence of ≥2 EN sites and bone involvement pattern were also predictive of OS in a univariate analysis. In a multivariate analysis with FLIPI‐2 factors, spleen involvement, pattern of bone involvement, and soft tissue involvement independently predicted a lower EFS (HR 1.49 (1.11‐2.00),P= .007; HR 1.71 (1.10‐2.65),P= .017; and HR 1.67 (1.06‐2.62),P= .026, respectively). When the multivariate analysis was performed using PRIMA‐PI factors (marrow and B2M), the number of EN sites was an independent prognostic factor for inferior OS (HR 2.28;P= .05). Baseline PET/CT identifies EN involvement in nearly half of patients with untreated FL. The presence of ≥2 EN sites, bone, soft tissue, or splenic involvement predicts early clinical failure. These results, when combined with other factors, may better identify high‐risk patients and guide therapy.